TOP OF THE NEWS
ment of infringement, while Cordis was
denied a request to delay jury trial.
The case concerns 2.25-millimeter
stents; Boston Scientific and Cordis are the
only U.S. manufacturers of these models.
Both companies accused the other of
patent infringement in 2003. The jury ruled
in favor of Boston Scientific on the grounds
that Cordis’ Cypher and BX Velocity stents
were in violation of the patent. The ruling
was upheld on appeal.
Boston Scientific’s triumph over Cordis
is a rare win for the company. The firm paid
$716 million to Cordis in 2009 to settle 14
patent infringement suits for stent technologies. Not included in that group was a
lawsuit regarding a drug-eluting stent. In
February, Boston Scientific was denied a
request to suspend the lawsuit pending review by the U.S. Patent and Trademark Office because it would give an unfair
disadvantage to Cordis.
New Device Firm Considers
Talent Pool in Location Decision
Breathe Technologies, Inc. is planning to
move its headquarters from San Roman,
Calif., to Orange County, Calif., by July.
CEO Larry Mastrovich said the company
most likely will settle in Irvine, Calif.
Company executives currently are
scouting buildings for the firm’s corporate
offices and manufacturing. They initially
expect to fill 25 jobs in sales and marketing, clinical, engineering, and operations
when the company opens in its new location, and an additional 45 positions in its
Talent recruitment was the primary factor
behind Breathe’s decision to move, according to Mastrovich. Chief competitors in the
area include CareFusion Corp. and ResMed
Corp. (both located in San Diego, Calif).
Breathe Technologies produces small
devices for the treatment of chronic ob-
structive pulmonary disease and sleep
apnea. The company recently received U.S.
Food and Drug Administration approval for
home use of its BT-VS2 portable ventilator.
Healthcare Changes Prompt
Medtronic to Merge Sales Force
Medtronic, Inc. is combining its U.S. Cardiac
and Vascular Group sales functions into one
unified cross-divisional sales organization.
The change was effective at the start of
Medtronic’s new fiscal year on May 1.
The change comes in response to the
challenges hospitals face as the healthcare
environment evolves, as well as the increasing importance of the hospital administrator in the device selection process.
“Medtronic’s new market strategy reflects how large hospital systems are making device selection decisions today,” said